Food, drug, insect sting allergy, and anaphylaxisReslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial
Section snippets
Patients
Male or female children and adolescents aged between 5 and 18 years with active eosinophilic esophagitis were eligible to participate in the study. Patients must have had at least 1 active symptom (ie, vomiting, regurgitation, abdominal pain, chest pain/heartburn, or dysphagia) of moderate severity or worse (as assessed by the patient) within the week before randomization, an esophagogastroduodenoscopy with biopsy documenting active eosinophilic esophagitis (defined as ≥24 eosinophils in ≥1
Study population
Of the 227 patients who were randomly assigned to treatment, 1 did not receive study medication (Fig 1). Thus 226 patients were included in the efficacy and safety analyses. Most patients were male and had a history of atopic disease (Table I). All patients had 24 or more esophageal eosinophils in the peak hpf at baseline, and the median number was 80.0 eosinophils/hpf for the population as a whole, with a range of 24 to 453 eosinophils/hpf.
Two patients in the 1 mg/kg reslizumab group, 3
Discussion
We evaluated the effect of reslizumab, an antibody to IL-5, in children and adolescents with eosinophilic esophagitis. The study population consisted of patients with long-standing disease, a mean of 4 years of eosinophilic esophagitis symptoms, and significant esophageal eosinophilia. Patients who received reslizumab showed statistically significant and clinically relevant reductions in esophageal eosinophil counts compared with those who received placebo. However, these reductions were not
References (22)
- et al.
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment
Gastroenterology
(2007) - et al.
A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis
Gastroenterology
(2006) - et al.
An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis
Gastroenterology
(2011) - et al.
Involvement of mast cells in eosinophilic esophagitis
J Allergy Clin Immunol
(2010) - et al.
Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies
J Allergy Clin Immunol
(2011) - et al.
Distinguishing eosinophilic esophagitis in pediatric patients: clinical, endoscopic, and histologic features of an emerging disorder
J Clin Gastroenterol
(2007) - et al.
Eosinophilic esophagitis: updated consensus recommendations for children and adults
J Allergy Clin Immunol
(2011) - et al.
The link between allergies and eosinophilic esophagitis: implications for management strategies
Expert Rev Clin Immunol
(2010) - et al.
Eosinophilic esophagitis
N Engl J Med
(2004) - et al.
IL-5 promotes eosinophil trafficking to the esophagus
J Immunol
(2002)
Fundamental signals that regulate eosinophil homing to the gastrointestinal tract
J Clin Invest
Cited by (0)
Sponsored by Ception Therapeutics, Inc, which has since been acquired by Cephalon, Inc.
Disclosure of potential conflict of interest: J. M. Spergel is a consultant for DBV; has received research support from the Department of Defense (DOD), Cephalon, and the National Institutes of Health (NIH); is a member of the American Academy of Allergy, Asthma & Immunology; and is on the American Partnership for Eosinophilic Disorders (APFED) Medical Advisory Board. M. E. Rothenberg has equity interest in reslizumab through Cephalon; is consultant and chief scientific officer of Immune Pharmaceuticals; has received research support from the NIH, the Food Allergy & Anaphylaxis Network, and the DOD; is on the APFED Medical Advisory Board; and is on the International Eosinophil Society Executive Council. M. H. Collins is a central review pathologist for Cephalon, GlaxoSmithKline, and Meritage Pharma; is a consultant for Sunovion; and is president of the APFED Medical Advisory Board. G. T. Furuta is a consultant for Nutricia and Meritage and has received research support from the NIH, AstraZeneca, and the Thrasher Foundation. G. Fuchs III has received research support from Shire and Cephalon. J. P. Abonia has received research support from the NIH, Ception Therapeutics, and the Children’s Digestive Health and Nutrition Foundation. T. Henkel is a consultant for Cephalon and a shareholder in Ception Therapeutics. C. A. Liacouras is a speaker for Nutricia and is on the American Partnership for Eosinophilic Disorders Physician Board. The rest of the authors declare that they have no relevant conflicts of interest.